That is the title of My commentary with co-authors Kathy Lang and Ross Maclean by doing Journal of Clinical Pathways. The summary is below.
What is the right price for a new treatment for COVID-19? A common approach, widely used by the Institute of Clinical and Economic Review worldwide and in the United States, measures treatment value based largely on quality adjusted life years (QALYs) that result from patient costs. However, in the case of COVID-19, it is clear that a new vaccine or treatment is valued by society far more than just the average QALYs received by patients with the disease. In this comment, the authors argue that the “Flower of Value” of the International Society for Pharmacoeconomics and Results Research provides a helpful framework for more accurately evaluating treatments – such as those for COVID-19 – that affect not only the lives of patients, but also Supervisors, employers and a wider society.
Read the whole article Here.
Note: We are not the author of this content. For the Authentic and complete version,
Check its Original Source